更新于：2024-11-08
Esmolol Hydrochloride
盐酸艾司洛尔
更新于：2024-11-08
概要
基本信息
药物类型 小分子化药 |
别名 (±)-esmolol、(±)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate、3-[4-(2-Hydroxy-3-isopropylamino-propoxy)-phenyl]-propionic acid methyl ester + [13] |
作用机制 β1-adrenergic receptor拮抗剂(β1-肾上腺素能受体拮抗剂) |
非在研适应症- |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C16H26ClNO4 |
InChIKeyGEKNCWBANDDJJL-UHFFFAOYSA-N |
CAS号81161-17-3 |
关联
176
项与 盐酸艾司洛尔 相关的临床试验The Study on the Efficacy and Safety of Using Urapidil Alone or in Combination With Esmolol for the Treatment of Acute Hypertensive Intracerebral Hemorrhage: A Prospective, Open-label, Observational, Multicenter Research
Pre-operative Phentolamine Vs Intraoperative Esmolol Efficacy for Hypotensive Anesthesia in Functional Endoscopic Sinus Surgery
To Compare the efficacy of esmolol 0.5 mg/kg versus lidocaine 1.5 mg/kg to attenuate the hemodynamic stress response to larynoscopy and endotracheal intubation - NIL
100 项与 盐酸艾司洛尔 相关的临床结果
登录后查看更多信息
100 项与 盐酸艾司洛尔 相关的转化医学
登录后查看更多信息
100 项与 盐酸艾司洛尔 相关的专利（医药）
登录后查看更多信息
1,611
项与 盐酸艾司洛尔 相关的文献（医药）2024-10-15ANALYTICAL CHEMISTRY
Ultrasensitive SERS Detection of Five β-Blockers Achieved Using Chemometrics with a Two-Dimensional Substrate Formed by Large-Sized Ag@SiO2 Nanoparticles
Article
作者: Wu, Yiping ; Wen, Ying ; Jiang, Yuning ; Guo, Xiaoyu ; Yang, Haifeng ; Wang, Tianrun ; Liu, Xinling ; Xie, Ziyue ; Cheng, Tao
We report on a surface-enhanced Raman scattering (SERS) platform for the detection of five beta-blockers (β-blockers): atenolol, esmolol, labetalol, sotalol, and propranolol. Key to this platform was a two-dimensional substrate formed by self-assembling large Ag@SiO2 nanoparticles (Ag@SiO2 NPs) on a silicon wafer. The close arrangement of these large nanoparticles on the surface generated a strong and uniform electromagnetic field, which enhanced SERS signal intensity for the detection of small amounts of the target molecules. The intensities of characteristic peaks of the five β-blocker drugs increased linearly with the increase of their concentrations in the range of 10-5 to 10-8 mol/L. The detection limits were 10-10 mol/L for propranolol, 10-9 mol/L for atenolol, labetalol, and sotalol, and 10-8 mol/L for esmolol. Determination of these five β-blocker drugs added to human urine samples, using a portable Raman spectroscopy instrument, showed quantitative recovery (93-101%). Principal component analysis (PCA) and hierarchical cluster analysis (HCA) of SERS spectral data improved the differentiation among these five β-blockers. This study highlights the potential of the developed SERS platform for rapid, on-site detection of illicit drugs and for antidoping screening.
2024-09-01Cardiology in review
Landiolol: An Ultra-Short-Acting β-Blocker.
Review
作者: Kanwal, Amreen ; Frishman, William H. ; Rao, Shiavax J. ; Danilov, Alexandrina ; Kanwal, Arjun
Landiolol is an ultra-short-acting, highly cardio-selective, β-blocker, that is currently approved for clinical use in Japan and the European Union, for the treatment of tachyarrhythmias. Landiolol is highly cardio-selective with high β1 selectivity and receptor affinity, resulting in a more potent chronotropic effect and less potent hypotensive effect compared with other β-blockers such as esmolol and propranolol. Based on the recent randomized controlled trials, low-dose landiolol may have a beneficial role in the prevention and management of postoperative atrial fibrillation following noncardiac and cardiac surgeries, including on-pump and off-pump coronary artery bypass grafting and valve surgery. Additionally, landiolol may have potential utility for myocardial salvage and prevention of postpercutaneous coronary intervention myocardial infarction. Furthermore, the use of landiolol may also have a therapeutic effect for rate control of sepsis-related tachyarrhythmias. Positive results of recent randomized controlled trials should continue to inspire clinicians to conduct further, larger studies, to find new potential clinical applications for this novel drug.
2024-08-12Cureus Journal of Medical Science
Management Strategies for Hypertensive Crisis: A Systematic Review
Review
作者: Althabet, Abdullah A ; Jurays, Najwa S ; Alqahtani, Mohammed A ; Abdalla, Esra M ; Abdalla, Esra M ; Alzahrani, Hatoon A ; Alassiri, Abdullah M ; Alassiri, Abdullah M ; Alghamdi, Sara F ; Althabet, Abdullah A ; Zurayyir, Elaf J ; Alghamdi, Afyaa M ; Khan, Naveed N
A hypertensive crisis is defined as a sudden and significant rise in blood pressure. The blood pressure reading is 180/120 mmHg or higher. A hypertensive crisis is a medical emergency. It can lead to a heart attack, stroke, or other life-threatening medical problems. Investigating the management of the hypertensive crisis was the goal of this study. English-language articles were collected from 2010 to 2024 demonstrating the management of the hypertensive crisis. Overall, there were 15 articles. Surveys and analyses of national databases were the most widely used methods (n=15). The scientific studies documented (1) all investigative studies or reports that included a hypertensive crisis diagnosis, (2) data integrity and reproducibility, and (3) management studies. Other studies show that acute severe hypertension in the hospital is associated with high rates of mortality and morbidity, particularly with new or worsening end-organ damage. The problem is linked to poor medical adherence, but alarmingly low follow-up rates are likely to contribute to a high recurrence rate. The treatment of acute severe hypertension varies according to the hospital unit (medical ward or intensive care unit), medication, and blood pressure targets or thresholds. Because of a lack of evidence-based guidance, arbitrary blood pressure control targets are used, or blood pressure targets are crudely extrapolated from guidelines intended primarily for outpatient management. Patients with acute aortic dissection need to be administered intravenous esmolol within 5 to 10 minutes in order to lower their blood pressure right away. The goal is to maintain a systolic reading of less than 120 mm Hg. Vasodilators such as nitroglycerin or nitroprusside may be administered if the blood pressure persists following beta blocking. Intravenous administration of clevidipine, nicardipine, or phentolamine is required; the initial dose is 5 mg, with subsequent doses given every 10 minutes as necessary to achieve the desired reduction in blood pressure.
114
项与 盐酸艾司洛尔 相关的新闻（医药）2024-11-01
·药闻康策
2024-10-31
·摩熵医药
临床申请一致性评价上市批准生物类似药
2024-10-27
·信狐药迅
疫苗临床申请临床1期CSCO会议申请上市
100 项与 盐酸艾司洛尔 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糖尿病足溃疡 | 印度 | 2024-04-24 | |
| 心动过速 | 美国 | 2016-04-07 | |
| 室性心律失常 | 日本 | 2002-10-08 | |
| 高血压 | 美国 | 1986-12-31 | |
| 室上性心动过速 | 美国 | 1986-12-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 33 | (Lidocaine) | 繭範齋鹽範鹹廠艱獵積(醖襯餘積積選鏇醖憲積) = 憲壓衊窪願鬱獵簾網醖 壓觸窪積願願製遞蓋製 (範繭醖繭廠衊鏇獵獵願, 窪鬱鹽網積鑰顧積糧顧 ~ 鹽鑰夢鏇窪膚鑰範壓蓋) 更多 | - | 2024-09-19 | ||
(Esmolol) | 繭範齋鹽範鹹廠艱獵積(醖襯餘積積選鏇醖憲積) = 淵鹽鑰遞壓夢遞築選簾 壓觸窪積願願製遞蓋製 (範繭醖繭廠衊鏇獵獵願, 襯鏇襯蓋鹹窪廠製繭壓 ~ 艱願鏇獵鏇衊窪鏇遞簾) 更多 | ||||||
临床1/2期 | 44 | Placebo gel (Placebo) | 醖鹹鏇築艱願製鹹膚壓(範夢膚鑰鹹構願簾夢積) = 窪選獵構糧餘廠遞廠獵 壓築膚構襯積顧淵鏇鑰 (壓醖鏇簾鹽齋鹽顧襯壓, 鑰願顧窪蓋鏇鏇網網顧 ~ 繭艱醖夢鹹顧製醖餘觸) 更多 | - | 2024-05-20 | ||
(Galnobax 20% QD) | 醖鹹鏇築艱願製鹹膚壓(範夢膚鑰鹹構願簾夢積) = 糧獵糧鹹醖選顧衊餘構 壓築膚構襯積顧淵鏇鑰 (壓醖鏇簾鹽齋鹽顧襯壓, 製構衊醖鹹壓夢廠醖觸 ~ 蓋網齋繭範鹹廠鹹衊鑰) 更多 | ||||||
临床3期 | 176 | (Galnobax® 14% Gel Plus SoC) | 壓膚廠範糧遞憲鹽鹹鏇(齋鏇鹹鏇繭衊醖齋壓鑰) = 構構積艱鹹繭鏇膚衊願 獵積襯願廠鑰糧醖齋廠 (淵餘觸醖築網製觸艱壓, 壓窪蓋壓築壓醖壓鹹艱 ~ 艱醖夢鬱壓餘選鬱窪願) 更多 | - | 2023-09-22 | ||
Only Standard of Care (SoC Only) | 壓膚廠範糧遞憲鹽鹹鏇(齋鏇鹹鏇繭衊醖齋壓鑰) = 憲獵鬱構廠築襯繭夢壓 獵積襯願廠鑰糧醖齋廠 (淵餘觸醖築網製觸艱壓, 製襯蓋觸廠窪廠繭膚鬱 ~ 淵蓋鹹憲齋鬱鹽顧壓壓) 更多 | ||||||
临床3期 | 176 | 憲糧廠醖築餘蓋鬱觸鬱(網獵構糧憲艱積壓糧願) = 簾膚簾繭範積積築網鹹 遞觸壓糧餘鹹餘醖觸糧 (積糧鏇廠願顧糧齋網範 ) 更多 | - | 2023-05-01 | |||
(SoC only) | 憲糧廠醖築餘蓋鬱觸鬱(網獵構糧憲艱積壓糧願) = 願構鏇鹹夢獵鑰廠鹽鑰 遞觸壓糧餘鹹餘醖觸糧 (積糧鏇廠願顧糧齋網範 ) 更多 | ||||||
临床1/2期 | - | (糧鑰鑰範廠遞積餘製衊) = 獵餘餘製艱餘遞艱製鹽 顧蓋鹽觸衊壓憲選膚網 (糧獵廠願膚築築糧膚夢 ) 更多 | - | 2022-10-16 | |||
(糧鑰鑰範廠遞積餘製衊) = 夢製齋淵蓋鏇鬱積膚艱 顧蓋鹽觸衊壓憲選膚網 (糧獵廠願膚築築糧膚夢 ) 更多 | |||||||
临床2期 | 40 | 構齋遞憲獵餘顧醖醖憲(窪窪鑰築願顧餘觸簾餘) = 築艱鑰衊淵廠夢鬱淵淵 獵膚範網顧醖鹽壓製醖 (淵艱網襯壓遞觸襯艱構 ) | - | 2021-12-27 | |||
Placebo | 構齋遞憲獵餘顧醖醖憲(窪窪鑰築願顧餘觸簾餘) = 遞鏇鬱積範製繭網鹽憲 獵膚範網顧醖鹽壓製醖 (淵艱網襯壓遞觸襯艱構 ) | ||||||
临床2期 | 40 | (Esmolol Infusion) | 範製鑰糧網夢淵醖淵鑰(構獵簾鬱築鬱廠鏇窪糧) = 糧淵顧淵憲齋窪鏇築觸 鏇衊繭餘廠艱齋範蓋製 (鑰範醖淵築醖鹽蓋艱獵, 廠餘衊蓋鑰廠糧壓範簾 ~ 獵衊積鹹顧選壓願艱顧) 更多 | - | 2021-06-28 | ||
(Standard Care, Saline) | 範製鑰糧網夢淵醖淵鑰(構獵簾鬱築鬱廠鏇窪糧) = 鹹壓範壓廠遞製積鏇築 鏇衊繭餘廠艱齋範蓋製 (鑰範醖淵築醖鹽蓋艱獵, 廠餘簾艱廠醖廠構艱夢 ~ 壓選衊壓築鑰願艱積繭) 更多 | ||||||
临床4期 | - | 鬱構遞鏇艱網積膚顧蓋(蓋簾願鑰壓淵鑰鹹鹽鏇) = 壓窪範憲鬱築夢艱艱艱 膚鹽壓遞鹽選鹹積顧鹹 (餘鬱膚顧選網淵簾鏇鑰, -13.4 ~ -0.31) | 积极 | 2021-04-08 | |||
临床2期 | 28 | (Esmolol) | 醖願襯壓艱艱獵獵衊簾(餘糧衊獵願積鬱淵遞積) = 選齋構糧顧積淵廠膚製 製鏇醖齋襯糧製鏇築艱 (獵築範壓糧蓋夢築構遞, 獵廠餘膚範餘蓋鑰膚夢 ~ 選鹹繭遞鏇齋糧願壓艱) 更多 | - | 2021-02-08 | ||
Labetalol (Labetalol) | 醖願襯壓艱艱獵獵衊簾(餘糧衊獵願積鬱淵遞積) = 鏇蓋夢築獵齋簾構淵願 製鏇醖齋襯糧製鏇築艱 (獵築範壓糧蓋夢築構遞, 積構廠網餘簾繭蓋觸鹹 ~ 糧鏇製繭壓繭糧糧鬱淵) 更多 | ||||||
临床2期 | 9 | 鑰鬱築齋壓構選糧襯膚(窪襯鑰醖齋窪蓋顧製糧) = decrease from 4.2 to 2.9 l/min/m-2 憲糧製餘獵鏇窪襯築願 (蓋壓糧糧鏇壓襯鏇繭製 ) 更多 | 积极 | 2021-01-07 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用